Business context and reporting period
This filing is Ekso Bionics Holdings, Inc.’s Form 10-K for the fiscal year ended December 31, 2016, with unaudited fourth-quarter results. The filing does not identify Chronoscale Holdings Corp. as the registrant. Ekso designs and sells wearable exoskeletons for medical rehabilitation and industrial uses; it reported Medical Devices, Industrial Sales, and Engineering Services segments.
Financial results and liquidity
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Revenue | $14.2 million | $8.7 million |
| Gross profit (margin) | $2.9 million (20.7%) | $1.2 million (13.6%) |
| Operating loss | $27.6 million | $21.6 million |
| Net loss | $23.5 million | $19.6 million |
| Net loss applicable to common shareholders | $33.8 million | $24.2 million |
| Basic loss per share | $1.87 | $1.66 |
| Cash used in operating activities | $25.0 million | $18.3 million |
| Cash and cash equivalents at year-end | $16.8 million | $19.6 million |
| Total assets | $24.4 million | $32.2 million |
| Term loan, net | $6.8 million | None reported |
Amounts are in U.S. dollars. FY 2016 revenue comprised $12.1 million from Medical Devices, $1.3 million from Industrial Sales, and $0.9 million from Engineering Services. Segment gross profit was $2.3 million, $0.3 million, and $0.3 million, respectively.
For Q4 2016, revenue was $2.6 million, gross profit $0.8 million, net loss $5.6 million, and net loss applicable to common shareholders $5.6 million. Basic loss per share was $0.29.
Material changes versus the prior period
- Revenue rose 64%, but the comparison is significantly affected by a 2016 change in medical-device revenue recognition. The company recognized $6.5 million of previously deferred revenue and $4.2 million of related costs, adding $2.4 million to gross profit and reducing net loss applicable to common shareholders by $2.4 million, or $0.13 per share.
- Device and related revenue increased to $13.3 million from $4.3 million; Engineering Services revenue declined to $0.9 million from $4.4 million after the company shifted engineering resources toward internal product development.
- Operating expenses increased 34% to $30.5 million, including higher sales and marketing, R&D, and general and administrative costs. Operating loss widened by $6.0 million.
- Reported net loss included a $4.3 million non-cash gain from revaluation of warrant liabilities. Preferred-stock conversions resulted in a $10.3 million non-cash deemed dividend, increasing the loss applicable to common shareholders.
- Cash used in operations increased to $25.0 million. Financing activities provided $23.3 million, including $14.7 million net proceeds from a common-stock offering, $1.8 million from warrant exercises, and $6.9 million from debt issuance.
Outlook, risks and unusual items
Management estimated existing resources would fund obligations only into the third quarter of 2017 under its assumptions and stated that significant additional financing would be required. The company said it was pursuing equity or debt financing, collaborations, and warrant exercises; there is no assurance financing would be available on acceptable terms. The auditor’s report includes an explanatory paragraph expressing substantial doubt about the company’s ability to continue as a going concern.
Management’s 2017 priorities included expanding North American and European rehabilitation sales, adding Ekso GT software and analytics capabilities, continuing enrollment in the WISE clinical study, developing a home-use device, and expanding industrial sales of EksoZeroG. The filing provides no quantified revenue, earnings, or cash-flow guidance.
Key risks include ongoing losses and cash burn, capital-raising and dilution risk, uncertain market adoption and reimbursement, long hospital sales cycles, regulatory and clinical-trial requirements, competition, product safety and service costs, and supplier and intellectual-property risks. The company reported seven FDA-reportable device events since July 2015, with no reported patient injuries; it had taken corrective measures. FDA inspection observations from 2015 were addressed, and the FDA accepted the corrective actions in March 2016. The filing reported no material legal proceedings. The 2016 financial statements received an unqualified audit opinion; management and the auditor concluded internal control over financial reporting was effective.
Important facts for investors to verify
- Whether the company obtained financing after the filing date and its resulting cash runway, unrestricted cash, and compliance with the lender’s liquidity covenant.
- How much of subsequent revenue growth reflects actual device shipments and recurring service income versus the one-time recognition of deferred revenue.
- Quarterly device sales, gross margins, service and warranty costs, and the pace of adoption in medical and industrial markets.
- Progress and outcomes of WISE and other clinical studies, as well as payer coverage, reimbursement, and any new CPT-code efforts.
- Potential dilution from outstanding warrants and options, and the terms and obligations of the secured term loan.